Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck KGaA, Darmstadt, Germany
Essential hypertension is a heterogenous multifactorial disease affecting large number of population. Monotherapy treatment in hypertension is often unable to achieve the desired blood pressure (BP) goals and subjects even remain at significant risk for developing cardiovascular disease. The use of combination therapy as first line treatment for hypertension provides a solution to the management problems related to hypertension. Among combination drugs, low dose combinations are useful tools in treating large segments of hypertensive subjects because of their several advantages, such as simplified dosage regimens, improve compliance and hypertensive control, decrease dose dependent side effects as well as reduce costs.
OBJECTIVES
Primary objective:
* To evaluate the efficacy of Lodoz therapy when used in routine clinical practice in subjects with mild to moderate essential hypertension.
Secondary objective:
* To evaluate the discontinuation rate of Lodoz therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent
Subjects diagnosed with mild to moderate essential hypertension
Subjects foreseen for Lodoz treatment for hypertension
Age ≥ 18 years
You may not be if
Subjects treated with Lodoz before study initiation
Subjects who are pregnant
Subjects with any known contraindications to Lodoz based on local label